Section 232 Pharma Tariffs: How They Change CDMO Choice

Short answer: Section 232 pharmaceutical tariffs apply to imported patented drugs and their ingredients, with rates from 0% to 100% depending on where the product comes from and what agreements the company holds. For every company outside the 17 named in Annex III, duties start on September 29, 2026. For a European biotech, that makes CDMO location, origin documentation and contract clauses part of your US launch economics, not a procurement detail.

What do the Section 232 pharmaceutical tariffs actually do?

On April 2, 2026, the President signed the proclamation "Adjusting Imports of Pharmaceuticals and Pharmaceutical Ingredients into the United States" (Proclamation 11020). It sets a default 100% ad valorem duty on covered patented pharmaceutical products and associated ingredients, then layers lower rates on top. Where more than one rate could apply, CBP guidance says importers use the lowest applicable rate.

Generics and their ingredients, including biosimilars, are excluded "at this time." Commerce must report within one year of the proclamation on whether generic imports warrant action, so that exclusion is not permanent.

The specialty exemption matters for many European biotechs working in rare disease, cell and gene therapy or ADCs. It is conditional: the product must come from a jurisdiction with a trade and security framework agreement, or meet an urgent US health need.

When do the tariffs hit companies outside Annex III?

Duties started on July 31, 2026 for the 17 large companies listed in Annex III. Since that date, CBP has required importers of other companies' patented products to report heading 9903.04.61 at 0%. On September 29, 2026, that grace period ends and the substantive rates apply to everyone else.

If you have commercial product, or a partner importing your product, the entries clearing after September 29 carry the new duty. There is no in-transit exception in the CBP guidance; what counts is entry.

Why does CDMO location now drive landed cost?

The rate attaches to the country of origin of the imported product. A drug product of an EU member state lands at 15%. The same product of a country with no reduced rate, and no company agreement, lands at 100%. US-origin product is not tariffed.

That changes how you compare CDMO quotes. A lower per-batch price from a site outside the EU, Japan, South Korea, Switzerland or the UK can be wiped out on the first commercial shipment. CBP's guidance also lists 0% treatment for certain dosage forms made with US-origin APIs, which makes API origin a lever, not just finished product origin.

Origin for pharmaceuticals turns on where the product is substantially transformed, and multi-site supply chains (API in one country, drug product in another, packaging in a third) do not have an obvious answer. Get a written origin position for each supply route before you lock a CDMO.

*Tariff and origin treatment here is general information, not legal advice; confirm your specific position with trade counsel.*

Can a CDMO-made product qualify for the onshoring rate?

Yes, in principle. Commerce's Federal Register notice of May 13, 2026 asks applicants whether manufacturing is in their own facilities or at "contract manufacturers," and allows onshoring "including through the use of contract manufacturers." Using a CDMO does not by itself disqualify a company.

The constraints sit elsewhere. Applications were requested by June 12, 2026, and the notice does not set out a process for later applicants. Preferential treatment does not automatically cover products a company acquires or licenses after April 2, 2026, or products it did not develop "as a majority participant," unless Commerce approves.

That last point matters if your exit is a US out-licensing deal. A partner's existing onshoring rate may not extend to your asset by default. Raise it in term sheet discussions, not after signing.

What should change in your CDMO contract?

Most European CDMO agreements were drafted when US duty on pharmaceuticals was negligible. Four areas need revisiting:

For screening CDMOs on BIOSECURE exposure and FDA PreCheck, see our US CDMO and CRO selection guide. For core selection criteria, see how to choose a CDMO.

How should you model Section 232 tariff cost?

Build duty into cost of goods per US unit, by supply route, not as a single line in the P&L. For each route, model:

Investors and partners will ask for this in diligence. A route-by-route table is easier to defend than a blended assumption.

What are the options for US fill-finish?

Moving fill-finish to the US does not automatically make the product US-origin. Whether it does depends on origin rules applied to your specific product and process. Where US-origin API is used, CBP's 0% treatment for certain dosage forms is worth testing.

When you evaluate US fill-finish sites, add one quality question. FDA's CDER runs a voluntary Quality Management Maturity (QMM) prototype assessment program. Its Federal Register notice of February 11, 2026 invited up to nine establishments for the third cohort, with requests accepted through April 13, 2026, and contract manufacturing and testing organizations were not excluded. Ask candidate sites whether they have taken part, and what they learned. A site that has been through a QMM assessment can speak to its quality system beyond CGMP minimums.

If you are working through regulatory sequencing for a US filing, our FDA pathways overview sets out the options.

Section 232 CDMO checklist

• Confirm whether your product is a covered patented product, a generic or biosimilar, or a specialty product
• Map origin of API, drug substance, drug product and packaging for each supply route
• Obtain a written origin and tariff position from trade counsel
• Model landed cost per US unit at 15%, 100% and any exemption rate
• Add origin, tariff allocation, site change and notification clauses to CDMO contracts
• Check whether US partners' onshoring treatment covers in-licensed assets
• Ask US fill-finish candidates about QMM participation
• Re-test assumptions against the 2029 and 2030 rate changes

Show PXM what you are building

If US tariffs are reshaping your CDMO plan, PXM works inside your team. Through our Operate practice, senior PXM operators step in as fractional heads of CMC, regulatory and BD to run CDMO selection, contract terms and cost modelling. See our CMC strategy work, then tell us what you are building.

Sources